Neurogene Stock Performance
| NGNE Stock | 31.02 1.04 3.24% |
On a scale of 0 to 100, Neurogene holds a performance score of 9. The company secures a Beta (Market Risk) of 1.28, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurogene will likely underperform. Please check Neurogene's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Neurogene's current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Neurogene are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Neurogene exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 7.26 | Five Day Return 4.36 | Year To Date Return 40.06 | Ten Year Return (89.24) | All Time Return (86.59) |
Last Split Factor 1:4 | Last Split Date 2023-12-19 |
1 | Technical Heatmap Flags Neurogene Inc. for Watch - 2025 Market Outlook Free High Return Stock Watch Alerts - | 08/14/2025 |
2 | How sentiment analysis helps forecast Neurogene Inc. - 2025 Market Overview High Accuracy Swing Entry Alerts - Newser | 09/02/2025 |
3 | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 09/05/2025 |
4 | Nuveen LLC Purchases Shares of 27,482 Neurogene Inc. NGNE - MarketBeat | 09/11/2025 |
5 | AI Stocks Will Neurogene Inc outperform the market in YEAR - 2025 Major Catalysts Safe Capital Allocation Plans - | 09/18/2025 |
6 | How Neurogene Inc. stock responds to job market shifts - July 2025 Recap Low Risk Growth Stock Ideas - newser.com | 09/29/2025 |
7 | HC Wainwright Reiterates Buy Rating for Neurogene - MarketBeat | 10/10/2025 |
8 | How Neurogene Inc. stock reacts to Fed tightening - July 2025 Macro Moves Weekly Hot Stock Watchlists - nchmf.gov.vn | 10/20/2025 |
9 | Why Neurogene Inc. stock could break out in 2025 - Earnings Risk Report Safe Entry Zone Identification - newser.com | 10/24/2025 |
10 | Is Neurogene Inc. stock a buy before new product rollout - Weekly Profit Summary Low Risk High Win Rate Picks - newser.com | 10/27/2025 |
| Begin Period Cash Flow | 148.7 M | |
| Total Cashflows From Investing Activities | -125.3 M |
Neurogene | Build AI portfolio with Neurogene Stock |
Neurogene Relative Risk vs. Return Landscape
If you would invest 2,187 in Neurogene on July 30, 2025 and sell it today you would earn a total of 915.00 from holding Neurogene or generate 41.84% return on investment over 90 days. Neurogene is currently generating 0.6982% in daily expected returns and assumes 5.6345% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Neurogene, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurogene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurogene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurogene, and traders can use it to determine the average amount a Neurogene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1239
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NGNE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.63 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.7 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Neurogene is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurogene by adding it to a well-diversified portfolio.
Neurogene Fundamentals Growth
Neurogene Stock prices reflect investors' perceptions of the future prospects and financial health of Neurogene, and Neurogene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurogene Stock performance.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 37.76 M | ||||
| Shares Outstanding | 14.27 M | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 313.77 X | ||||
| Revenue | 925 K | ||||
| Gross Profit | (68.76 M) | ||||
| EBITDA | (71.89 M) | ||||
| Net Income | (75.14 M) | ||||
| Total Debt | 12.43 M | ||||
| Book Value Per Share | 19.15 X | ||||
| Cash Flow From Operations | (70.6 M) | ||||
| Earnings Per Share | (4.31) X | ||||
| Market Capitalization | 426.59 M | ||||
| Total Asset | 335.73 M | ||||
| Retained Earnings | (262.3 M) | ||||
| Working Capital | 300.77 M | ||||
About Neurogene Performance
By analyzing Neurogene's fundamental ratios, stakeholders can gain valuable insights into Neurogene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neurogene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurogene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 141.58 | 236.37 | |
| Return On Tangible Assets | (0.22) | (0.24) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.22) | (0.24) | |
| Return On Equity | (0.24) | (0.25) |
Things to note about Neurogene performance evaluation
Checking the ongoing alerts about Neurogene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurogene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurogene is way too risky over 90 days horizon | |
| Neurogene appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 925 K. Net Loss for the year was (75.14 M) with loss before overhead, payroll, taxes, and interest of (68.76 M). | |
| Neurogene generates negative cash flow from operations | |
| Neurogene has a frail financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Is Neurogene Inc. stock a buy before new product rollout - Weekly Profit Summary Low Risk High Win Rate Picks - newser.com |
- Analyzing Neurogene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurogene's stock is overvalued or undervalued compared to its peers.
- Examining Neurogene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurogene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurogene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurogene's stock. These opinions can provide insight into Neurogene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neurogene Stock analysis
When running Neurogene's price analysis, check to measure Neurogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurogene is operating at the current time. Most of Neurogene's value examination focuses on studying past and present price action to predict the probability of Neurogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurogene's price. Additionally, you may evaluate how the addition of Neurogene to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |